



Rayhaneh Afjei

Life Science Research Professional, Rad/Neuroimaging and Neurointervention

Publications

PUBLICATIONS

- **Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo.** *Journal of controlled release : official journal of the Controlled Release Society*
Wischhusen, J. C., Chowdhury, S. M., Lee, T., Wang, H., Bachawal, S., Devulapally, R., Afjei, R., Sukumar, U. K., Paulmurugan, R.
2020
- **TARGETED POLYIONS ENGINEERED WITH SURFACE miRNAs FOR COMBINED MULTIMODALITY IMAGING AND ENHANCEMENT OF TEMOZOLOMIDE TREATMENT: A NOVEL INTRANASALLY-DELIVERED THERANOSTIC STRATEGY AGAINST GLIOBLASTOMA**
Sukumar, U., Afjei, R., Massoud, T., Paulmurugan, R.
OXFORD UNIV PRESS INC.2019: 87–88
- **PRECEDING p53 STABILIZATION USING DOXORUBICIN AUGMENTS PRIMA-1-MEDIATED p53 REFOLDING AND INCREASED CELLULAR APOPTOSIS: EVALUATION OF A SEQUENTIAL COMBINATION THERAPY AGAINST GLIOBLASTOMA**
Babikir, H., Afjei, R., Paulmurugan, R., Massoud, T.
OXFORD UNIV PRESS INC.2019: 88
- **Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.** *Biomaterials*
Sukumar, U. K., Bose, R. J., Malhotra, M., Babikir, H. A., Afjei, R., Robinson, E., Zeng, Y., Chang, E., Habte, F., Sinclair, R., Gambhir, S. S., Massoud, T. F., Paulmurugan, et al
2019; 218: 119342
- **Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events in vivo** *THERANOSTICS*
Nishihara, R., Paulmurugan, R., Nakajima, T., Yamamoto, E., Natarajan, A., Afjei, R., Hiruta, Y., Iwasawa, N., Nishiyama, S., Citterio, D., Sato, M., Kim, S., Suzuki, et al
2019; 9 (9): 2646–61
- **Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events in vivo.** *Theranostics*
Nishihara, R., Paulmurugan, R., Nakajima, T., Yamamoto, E., Natarajan, A., Afjei, R., Hiruta, Y., Iwasawa, N., Nishiyama, S., Citterio, D., Sato, M., Kim, S. B., Suzuki, et al
2019; 9 (9): 2646–61
- **Comparison of cell-based assays to quantify treatment effects of anticancer drugs identifies a new application for Bodipy-L-cystine to measure apoptosis.** *Scientific reports*
Kumar, N., Afjei, R., Massoud, T. F., Paulmurugan, R.
2018; 8 (1): 16363
- **A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells.** *Oncotarget*
Paulmurugan, R., Afjei, R., Sekar, T. V., Babikir, H. A., Massoud, T. F.
2018; 9 (30): 21495–511

- **Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model.** *Oncotarget*
Malhotra, M., Sekar, T. V., Ananta, J. S., Devulapally, R., Afjei, R., Babikir, H. A., Paulmurugan, R., Massoud, T. F.
2018; 9 (30): 21478–94
- **Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.** *Cancer treatment reviews*
Babikir, H. A., Afjei, R., Paulmurugan, R., Massoud, T. F.
2018; 71: 19–31
- **Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents.** *ACS nano*
Je Bose, R., Uday Kumar, S., Zeng, Y., Afjei, R., Robinson, E., Lau, K., Bermudez, A., Habte, F., Pitteri, S. J., Sinclair, R., Willmann, J. K., Massoud, T. F., Gambhir, et al
2018
- **Engineering Intracellularly Retained Gaussia Luciferase Reporters for Improved Biosensing and Molecular Imaging Applications.** *ACS chemical biology*
Gaur, S., Bhargava-Shah, A., Hori, S., Afjei, R., Sekar, T. V., Gambhir, S. S., Massoud, T. F., Paulmurugan, R.
2017